Italian authorities raid Mylan offices for info on drug sales, hospital relationship

Mylan is now under investigation in Italy, fielding questions about its relationship with a hospital and about reimbursements for certain products, the company reported. (Pixabay)

Mylan has faced heaps of scrutiny into its business practices in recent years, including EpiPen price-hike hearings on Capitol Hill and a generic price-fixing investigation in the U.S. that's still playing out. Now, it can add another probe in Europe to the mix.

Investigators in Italy served Mylan employees search warrants last month "seeking information concerning interactions with an Italian hospital and sales of certain reimbursable Mylan" drugs, the company reported in a new quarterly filing with the Securities and Exchange Commission. 

"The Company is assisting its employees in their cooperation with the investigation," the filing says.  A Mylan representative didn't immediately respond to a request seeking more details. 

RELATED: Mylan President Rajiv Malik targeted as states expand price-fixing suit against top drugmakers 

As the situation in Italy plays out, Mylan also faces a probe of possible generic drug price-fixing in the U.S. State attorneys general have already filed a civil complaint against 18 drug companies and two executives, including Mylan's president, Rajiv Malik. The company said it's standing by Malik and that its internal investigation yielded no evidence of price-fixing. 

Federal prosecutors, meanwhile, are nearly ready to charge two companies and several executives for their role in the situation, Bloomberg recently reported, citing sources, who didn't disclose company or executive names. The news service also reported that the feds raided Mylan's headquarters in September 2016 when CEO Heather Bresch was testifying to Congress about EpiPen price hikes.

RELATED: Feds almost ready to charge drugmakers—and executives—in generics price-fixing probe

Mylan ran into its EpiPen pricing scandal in the fall of 2015. The company had raised the price of the epinephrine injector repeatedly—multiplying the cost fourfold between 2009 and 2016—and the hikes combined with higher deductibles left patients with high costs. Patients' anger turned into Congressional probes and more, and now the company's key product is suffering from increased competition.